Altering the Brain's Chemistry
to Elevate Mood
By Donald Brown, N.D., Alan R.
Gaby, M.D., and Ronald Reichert, N.D.
Depression is one of the most frequent psychological
problems encountered in medical practice. Some studies say 13 to 20 percent of
American adults exhibit some depressive symptoms.1 The mortality
rate among those who are depressed is four times greater than those without
depressionmajor
depression accounts for 60 percent of all suicides.2
Yet, despite this professional recognition and
the fact that depression is a treatable condition, only about a
third of depressed
patients receive appropriate intervention.2
While the exact
etiology of depression is
unknown, numerous factors appear to contribute. These include genetics,
life/event sensitization and biochemical changes.
Family, twin and adoption studies demonstrate
that predisposition toward depression can be inherited. In addition, stressful
life events can contribute to depression; most studies concur that the
likelihood of a depressive episode is five to six times greater six months
after events such as early parental loss, job loss or divorce. The link between
depression and stressful life events has been conceptualized in the form of the
sensitization model, which proposes that prior exposure to stressful life
events sensitizes the brain's limbic system to the degree that subsequently
less stress is needed to produce a mood disorder.3 Many of the
current biochemical theories of depression focus on the biogenic amines, which
are a group of chemical compounds important in neurotransmissionmost
importantly norepinephrine, serotonin and, to a lesser extent, dopamine,
acetylcholine and epinephrine.
Antidepressant medications, which address the brain's
biochemistry, include monoamine oxidase (MAO) inhibitors, tricyclic
antidepressants and selective serotonin reuptake inhibitors. MAOs increase
norepinephrine levels, while tricyclics essentially enhance norepinephrine
transmission. Serotonin, in particular, has been the subject of intense
research during the past 25 years, indicating its importance in the
pathophysiology of depression. Basically, a functional deficiency in serotonin
results in depression.4
Amino Acid Supplements
The nutritional treatment of depression includes dietary
modifications, supportive treatment with vitamins and minerals, and
supplementation with
specific amino acids, which are precursors to neurotransmitters. Dietary
modification and vitamin and mineral supplementation in some cases reduce the
severity of depression or result in an improvement in general well-being.
However, these interventions are usually considered adjunctive, since they are
not typically effective by themselves as a treatment for clinical depression.
On the other hand, supplementation with the amino acids L-tyrosine and
D,L-phenylalanine can in many cases be used as an alternative to antidepressant
drugs. Another particularly effective treatment is the amino acid L-tryptophan
(see sidebar).
L-Tyrosine is the precursor to the
biogenic amine norepinephrine and may therefore be valuable to the subset of
people who fail to respond to all medications except amphetamines. Such people
excrete much less than the usual amounts of 3-methoxy-4-hydroxyphenylglycol,
the byproduct of norepinephrine breakdown, suggesting a deficiency of brain
norepinephrine.
One clinical study detailed two patients with
long-standing depression who failed to respond to MAO inhibitor and tricyclic
drugs as well as electroconvulsive therapy.5 One patient required 20
mg/day of dextroamphetamine to remain depression-free, and the other required
15 mg/day of D,L-amphetamine. Within two weeks of starting L-tyrosine, 100
mg/kg once a day before breakfast, the first patient was able to eliminate all
dextroamphetamine, and the second was able to reduce the intake of
D,L-amphetamine to 5 mg/day. In another case report, a 30-year-old female with
a two-year history of depression showed marked improvement after two weeks of
treatment with L-tyrosine, 100 mg/kg/day in three divided doses.6 No
side effects were seen.
L-Phenylalanine, the naturally occurring
form of phenylalanine, is converted in the body to L-tyrosine. D-phenylalanine,
which does not normally occur in the body or in food, is metabolized to
phenylethylamine (PEA), an amphetaminelike compound that occurs normally in the
human brain and has been shown to have mood-elevating effects. Decreased
urinary levels of PEA (suggesting a deficiency) have been found in some
depressed patients.7 Although PEA can be synthesized from
L-phenylalanine, a large proportion of this amino acid is preferentially
converted to L-tyrosine. D-phenylalanine is therefore the preferred substrate
for increasing the synthesis of PEAalthough L-phenylalanine would also
have a mild antidepressant effect because of its conversion to L-tyrosine and
its partial conversion to PEA. Because D-phenylalanine is not widely available,
the mixture D,L-phenylalanine is often used when an antidepressant effect is
desired.
Studies of D,L-phenylalanine's efficacy show
that it has promise as an antidepressant. Additional research is needed to
determine the optimal dosage and which types of patients are most likely to
respond to treatment.
Vitamin and Mineral
Therapy
Vitamin and mineral deficiencies can cause
depression. Correcting deficiencies, when present, often relieves depression.
However, even if a deficiency cannot be demonstrated, nutritional
supplementation may improve symptoms in selected groups of depressed
patients.
Vitamin B6, or pyridoxine, is the
cofactor for enzymes that convert L-tryptophan to serotonin and L-tyrosine to
norepinephrine. Consequently, vitamin B6 deficiency might result in depression.
One person volunteered to eat a pyridoxine-free diet for 55 days. The resultant
depression was alleviated soon after supplementation with pyridoxine was
begun.8
While severe vitamin B6 deficiency is rare,
marginal vitamin B6 status may be relatively common. A study using a sensitive
enzymatic assay suggested the presence of subtle vitamin B6 deficiency among a
group of 21 healthy individuals.9 Vitamin B6 deficiency may also be
common in depressed patients. In one study, 21 percent of 101 depressed
outpatients had low plasma levels of the vitamin.10 In another
study, four of seven depressed patients had subnormal plasma concentrations of
pyridoxal phosphate, the biologically active form of vitamin B6.11
Although low vitamin B6 levels could be a result of dietary changes associated
with depression, vitamin B6 deficiency could also be a contributing factor to
the depression.
Depression is also a relatively common side
effect of oral contraceptives. The symptoms of contraceptive-induced depression
differ from those found in endogenous and reactive depression. Pessimism,
dissatisfaction, crying and tension predominate, whereas sleep disturbance and
appetite disorders are uncommon. Of 22 women with depression associated with
oral contraceptive use, 11 showed biochemical evidence of vitamin B6
deficiency. In a double-blind, crossover trial, women with vitamin B6
deficiency improved after treatment with pyridoxine, 2 mg twice a day for two
months.12 Women who were not deficient in the vitamin did not
respond to supplementation.
These studies indicate vitamin B6
supplementation is valuable for a subset of depressed patients. Because of its
role in monoamine metabolism, this vitamin should be investigated as possible
adjunctive treatment for other patients with depression. A typical vitamin B6
dose is 50 mg/day.
Folic acid
deficiency may result from dietary deficiency, physical or psychological
stress, excessive alcohol consumption, malabsorption or chronic diarrhea.
Deficiency may also occur during pregnancy or with the use of oral
contraceptives, other estrogen preparations or anticonvulsants. Psychiatric
symptoms of folate deficiency include depression, insomnia, anorexia,
forgetfulness, hyperirritability, apathy, fatigue and
anxiety.13
Serum folate levels were measured in 48
hospitalized patients: 16 with depression, 13 psychiatric patients who were not
depressed and 19 medical patients.14 Depressed patients had
significantly lower serum folate concentrations than did patients in the other
two groups. Depressed patients with low serum folate levels had higher
depression ratings on the Hamilton Depression Scale than did depressed patients
with normal folate levels.
These findings suggest that folic acid
deficiency may be a contributing factor in some cases of depression. Serum
folate levels should be determined in all depressed patients who are at risk
for folic acid deficiency. The usual dose of folic acid is 0.4 to 1 mg/day. It
should be noted that folic acid supplementation can mask the diagnosis of
vitamin B12 deficiency when the complete blood count is used as the sole
screening test. Patients in whom vitamin B12 deficiency is suspected and who
are taking folic acid should have their serum vitamin B12 measured.
Vitamin B12 deficiency can also manifest
as depression.15 In depressed patients with documented vitamin B12
deficiency, parenteral (intravenous) administration of the vitamin has resulted
in dramatic improvement.16 Vitamin B12, 1 mg/day for two days (route
of administration not specified), also produced rapid resolution of postpartum
psychosis in eight women.17
Vitamin C, as the cofactor for
tryptophan-5-hydroxylase, catalyzes the hydroxylation of tryptophan to
serotonin.18 Vitamin C may therefore be valuable for patients with
depression associated with low levels of serotonin. In one study, 40 chronic
psychiatric inpatients received 1 g/day of ascorbic acid or placebo for three
weeks, in double-blind fashion.19 In the vitamin C group,
significant improvements were seen in depressive, manic and paranoid symptom
complexes, as well as in overall functioning.
Magnesium
deficiency can cause numerous psychological changes, including depression. The
symptoms of magnesium deficiency are nonspecific and include poor attention,
memory loss, fear, restlessness, insomnia, tics, cramps and dizziness.20
Plasma magnesium levels have been found to be significantly lower in
depressed patients than in controls.21 These levels increased
significantly after recovery. In a study of more than 200 patients with
depression and/or chronic pain, 75 percent had white blood cell magnesium
levels below normal.22 In many of these patients, intravenous
magnesium administration led to rapid resolution of symptoms. Muscle pain
responded most frequently, but depression also improved.
Magnesium has also been used to treat
premenstrual mood changes. In a double-blind trial, 32 women with premenstrual
syndrome were randomly assigned to receive 360 mg/day of magnesium or placebo
for two months.23 The treatments were given daily from day 15 of the
menstrual cycle until the onset of menstruation. Magnesium was significantly
more effective than placebo in relieving premenstrual symptoms related to mood
changes.
These studies suggest that magnesium deficiency
may be a factor in some cases of depression. Dietary surveys have shown that
many Americans fail to achieve the Recommended Dietary Allowance for
magnesium.24,25 As a result, subtle magnesium deficiency may be
common in the United States. A nutritional supplement that contains
200400 mg/day of magnesium may therefore improve mood in some patients
with depression.
Phytomedicine Considerations
* St. John's wort
(Hypericum perforatum) as a standardized extract is licensed in Germany
and other European countries as a treatment for mild to moderate depression,
anxiety and sleep disorders.
St.
John's wort has a complex and diverse chemical makeup. Hypericin and
pseudohypericin have received most of the attention based on their
contributions to both the antidepressive and antiviral properties of St. John's
wort. This explains why most modern St. John's wort extracts are standardized
to contain measured amounts of hypericin. Recent research, however, indicates
that the medicinal actions of St. John's wort can be ascribed to other
mechanisms of action and also to the complex interplay of many
constituents.26
While St. John's wort's ability to act as an
antidepressant is not fully understood, previous literature points to its
ability to inhibit MAOs. MAOs act by inhibiting MAO-A or -B isozymes, thereby
increasing synaptic levels of the biogenic amines, especially norepinephrine.
This earlier research showed that St. John's wort extracts not only inhibit
MAO-A and MAO-B but also reduce the availability of serotonin receptors,
resulting in the impaired uptake of serotonin by brain
neurons.27
More than 20 clinical studies have been
completed using several different St. John's wort extracts. Most have shown
antidepressant action either greater than placebo or equal in action to
standard prescription antidepressant drugs.28 A recent review
analyzed 12 controlled clinical trialsnine were placebo-controlled and
three compared St. John's wort extract to antidepressant drugs maprotiline or
imipramine.29 All trials showed greater antidepressant effect with
St. John's wort compared with placebo and comparable results with St. John's
wort as with the standard antidepressant medications. The first U.S.
government-sanctioned clinical trial of St. John's wort, a three-year study
sponsored by the Center for Complementary and Alternative Medicine, based in
Washington, D.C., began last year.
Dosage is typically based on hypericin
concentration in the extract. The minimum daily hypericin dosage recommended is
approximately 1 mg. For example, an extract standardized to contain 0.2 percent
hypericin would require a daily dosage of 500 mg, usually given in two divided
dosages. Clinical studies have used a St. John's wort extract standardized to
0.3 percent hypericin at a dose of 300 mg three times daily.
The German Commission E Monograph for St.
John's wort lists no contraindications to its use during pregnancy and
lactation.30 However, more safety studies are needed before St.
John's wort is recommended for this population.
Ginkgo (Ginkgo
biloba) extract, while clearly not a primary treatment of choice for most
patients with major depression, should be considered an alternative for elderly
patients with depression resistant to standard drug therapy. This is because
depression is often an early sign of cognitive decline and cerebrovascular
insufficiency in elderly patients. Frequently described as resistant
depression, this form of depression is often unresponsive to standard
antidepressant drugs or phytomedicines like St. John's wort. One study showed a
global reduction in regional cerebral blood flow in depressed patients older
than 50 when compared with age-matched, healthy controls.31
In that study, 40 patients, ages 51 to 78, with
a diagnosis of resistant depression (insufficient response to treatment with
tricyclic antidepressants for at least three months), were randomized to
receive either Ginkgo biloba extract or placebo for eight
weeks.32 Patients in the ginkgo group received 80 mg of the extract
three times daily. During the study, patients remained on their antidepressant
drugs. In patients treated with ginkgo, there was a decline in the median
Hamilton Depression Scale scores from 14 to 7 after four weeks. This score was
further reduced by 4.5 at eight weeks. There was a one-point reduction in the
placebo group after eight weeks. In addition to the significant improvement in
symptoms of depression for the ginkgo group, there was also a noted improvement
in overall cognitive function. No side effects were reported.
Many nutrition-oriented practitioners have
found that the answer to depression is as simple as one's diet. A diet low in
sugar and refined carbohydrates (with small, frequent meals) can produce
symptomatic relief in some depressed patients. Individuals most likely to
respond to this dietary approach are those who develop symptoms in the late
morning or late afternoon or after missing a meal. In these patients, ingestion
of sugar provides transient relief, followed by an exacerbation of symptoms
several hours later.
Donald Brown, N.D.,
teaches herbal medicine and therapeutic nutrition at Bastyr University,
Bothell, Wash. Alan R. Gaby, M.D., is past president of the American
Holistic Medical Association. Ronald Reichert, N.D., is an expert in
European phytotherapy and has an active medical practice in Vancouver, B.C.
Sidebars:
5-HTP and the
Serotonin Connection
Source: Excerpted with
permission from Depression (Natural Product Research Consultants, 1997).
Article references
here.
top ~
next ~
send page to a
friend
HealthyPlace.com
Depression Center Links
home ~ site map ~
causes ~ types ~
people ~
living with
treatments ~ self-help ~ support ~ suicide ~ related
issues
|